Sage Therapeutics Announces Second Quarter 2018 Financial Results and Highlights Pipeline and Business Progress

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. DFTX
6. GOOGL
7. APGE
8. MU
9. IBM
10. HOOD

Go back to Sage Therapeutics Announces Second Quarter 2018 Financial Results and Highlights Pipeline and Business Progress

SAGE Therapeutics (SAGE) Reports Q2 Loss of $0.36

August 7, 2018 6:34 AM EDT

SAGE Therapeutics (NASDAQ: SAGE) reported Q2 EPS of ($0.36), versus ($1.89) reported last year.

Conditional acceptance granted by U.S. Food and Drug Administration (FDA) for the proprietary name ZULRESSO for Sages intravenous formulation of brexanolone

Continuing to execute commercial build and launch readiness for ZULRESSO (brexanolone injection) in postpartum depression ahead of PDUFA target date of December 19, 2018

Accelerating... More